CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Translate Bio Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Translate Bio Inc
29 Hartwell Ave
Phone: (617) 945-7361p:617 945-7361 LEXINGTON, MA  02421-3102  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 9/14/2021.
This company ceased filing statements with the SEC on 9/24/2021.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Translate Bio, Inc. is a messenger RNA, or mRNA, therapeutics company. The Company is developing medicines to treat diseases caused by protein or gene dysfunction. The Company is using its proprietary mRNA therapeutic platform, or MRT platform, and it create mRNA that encodes functional proteins. The mRNA is delivered to the target cell where the cell’s own machinery recognizes it and translates it, restoring or augmenting protein function to treat or prevent disease. The MRT product candidate for the lung, MRT5005, is designed to address the underlying cause of CF by delivering mRNA encoding fully functional CFTR protein to the lung epithelial cells through nebulization.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202112/31/2020YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President Everett R.Sutherland 51 3/22/2021 3/22/2021
Chief Executive Officer, Director Ronald C.Renaud 52 4/19/2021 11/1/2014
Chief Financial Officer BrendanSmith 45 4/19/2021 4/19/2021
9 additional Officers and Directors records available in full report.

Business Names
Business Name
TBIO
Translate Bio MA, Inc.
Translate Bio Securities Corporation

General Information
Number of Employees: 122 (As of 12/31/2020)
Outstanding Shares: 75,586,714 (As of 8/2/2021)
Shareholders: 50
Stock Exchange: NASD
Federal Tax Id: 611807780
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 2, 2024